Bristol Myers Squibb Turns to China to Develop New Drugs in its Newest Cross-Continent Collaboration.

America’s largest pharmaceutical companies stated that they will partner with a Chinese drugmaker to test some of their experimental drugs and discover new ones. This deal could mark the next phase of coordination across continents.
The company has announced the potential multibillion-dollar partnership with one of China’s top drugmakers, Hengrui Pharma. This will help to work together to develop about a dozen drugs, including four that Bristol discovered and will send to China for Hengrui to run the early-stage clinical trials.

According to Towards Healthcare, the China pharmaceutical market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 93.11 billion in 2026 to approximately USD 183.66 billion by 2035, representing a compound annual growth rate (CAGR) of 7.84% from 2026 to 2035. Growth is driven by the increase in chronic diseases, urbanization, and changing lifestyles has led to a surge in chronic ailments, such as cardiovascular diseases, diabetes, and oncology requiring specialized treatments. This sustained demand for long-term care and medications related to age-related conditions, such as cardiovascular diseases, diabetes, and oncology, requires specialized treatments.

About Bristol Myers Squibb

Bristol Myers Squibb has signed a deal with Jiangsu Hengrui Medicine, China’s largest pharmaceutical company by market capitalisation. This agreement covers 13 early-stage drug programmes across oncology, haematology, and immunology. None of the drugs has entered human clinical trials. The deal was announced on the same day that President Trump flew to Beijing for his first state visit to China in his second term.

Michael Baran, head of private investments at healthcare-focused hedge fund Affinity Asset Advisors and a former partner at Pfizer Ventures, stated its huge signal that U.S. drugmakers have partnered with Chinese companies to develop drugs before, including Amgen’s 2019 collaboration with BeOne.

It helps to raise the prospect that more U.S. drugmakers could increasingly carry out early drug development in China as they try to bring treatments to market more quickly, and that Chinese companies could start to become global powerhouses.

A recent report by Towards Healthcare highlights that the China pharmaceutical market is witnessing growth driven by the aging population and a rising burden of chronic diseases, with massive demand for innovative oncology, cardiovascular, and diabetes therapies. With an aging population and a rising burden of chronic diseases, with massive demand for innovative oncology, cardiovascular, and diabetes therapies. Technological advancement treatments, particularly biologics, antibody-drug conjugates (ADCs), and cell therapies.